Stacey Cohen, MD, discusses the rationale and study design of the phase 2/3 CIRCULATE-NORTH AMERICA study evaluating adjuvant chemotherapy selection based on MRD, and the panel discusses barriers to enrollment.
FDA to Hold End-of-Phase 2 Meeting for Botensilimab Plus Balstilimab in R/R mCRC
Lunning and Rutherford Detail Considerations for BV-AVD Use in Older Patients With Hodgkin Lymphoma
Salvage Nivolumab/Ipilimumab Following Nivolumab Affords Treatment-Free Survival in RCC
Gutierrez and Leslie Discuss Recent Efforts and Future Advances in CAR T-Cell Therapy
Pooled Analysis Shows Cytoreduction to Be Safe, Tolerable in Younger Patients With PV
FDA Approves Noninvasive Stool RNA Screening Test for CRC
Capivasertib/Fulvestrant Improves PFS2 in Pretreated PIK3CA/AKT1/PTEN+ HR+/HER2– Breast Cancer
T-DXd Maintains Survival Advantage Over Physician’s Choice of Therapy in HER2+ Metastatic Breast Cancer
Ipatasertib/Anti-HER2 Therapy Is Safe and Active in PIK3CA-Mutant, HER2+ Advanced Breast Cancer
Dato-DXd Reduces High-Grade TRAEs vs Chemo in Pretreated, HR+/HER2– Advanced Breast Cancer